Tucidinostat is a benzamide-based histone deacetylase inhibitor (HDACi). Under physiological concentration in patients, it exerts significant inhibition on the enzymatic activities of HDAC subtypes 1, 2, 3, and 10, but not on the activities of other subtypes.
Figure 1. Tucidinostat possible anti-cancer mechanism.